Herbal granules aim to ease breathing in lung disease trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 to 75 years old, regardless of sex. * Diagnosed with bronchiectasis confirmed by High-Resolution Computed Tomography (HRCT) scan. * Bronchiectasis is currently in the stable phase. * Experienced at least one acute exacerbation of bronchiectasis within the previous 12 months. * Diagnosed with the Traditional Chinese Medicine (TCM) syndrome of "Phlegm-Heat Obstructing the Lungs". * Able to understand the study protocol and voluntarily sign the informed consent form. Exclusion Criteria: * Allergic to any ingredients of the investigational drug or placebo. * Comorbid with other severe systemic diseases (e.g., coronary heart disease, stroke, severe hypertension \[systolic BP ≥ 180 mmHg or diastolic BP ≥ 110 mmHg\], active gastric ulcer, uncontrolled diabetes \[fasting venous blood glucose ≥ 10 mmol/L\], malignant tumors, abnormal liver or kidney function \[AST, ALT, or GGT \> 2 times the upper limit of normal; or serum creatinine \> 2 times the upper limit of normal\]) or psychiatric disorders. * Comorbid with asthma, allergic bronchopulmonary aspergillosis (ABPA), or active pulmonary tuberculosis. * Comorbid with chronic obstructive pulmonary disease (COPD) and presenting COPD as the primary clinical manifestation (as judged by the investigator). * Use of inhaled, oral, or intravenous antibiotics within 4 weeks prior to enrollment. * Type 2 respiratory failure requiring long-term non-invasive mechanical ventilation or oxygen therapy (\> 10 hours/day). * History of drug abuse, psychotropic drug dependence, or alcohol abuse. * Current smokers or those unable to stop smoking during the study. * Pregnant or lactating women, planning to become pregnant during the study, or refusing to use reliable contraceptive methods throughout the study period. * Participation in any other clinical trials within 3 months prior to enrollment. * Considered unsuitable for participation in this clinical study by the investigator.